These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

556 related items for PubMed ID: 24821649

  • 1. Synergistic cytotoxicity of the poly (ADP-ribose) polymerase inhibitor ABT-888 and temozolomide in dual-drug targeted magnetic nanoparticles.
    Muñoz-Gámez JA, López Viota J, Barrientos A, Carazo Á, Sanjuán-Nuñez L, Quiles-Perez R, Muñoz-de-Rueda P, Delgado Á, Ruiz-Extremera Á, Salmerón J.
    Liver Int; 2015 Apr; 35(4):1430-41. PubMed ID: 24821649
    [Abstract] [Full Text] [Related]

  • 2. The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
    Palma JP, Rodriguez LE, Bontcheva-Diaz VD, Bouska JJ, Bukofzer G, Colon-Lopez M, Guan R, Jarvis K, Johnson EF, Klinghofer V, Liu X, Olson A, Saltarelli MJ, Shi Y, Stavropoulos JA, Zhu GD, Penning TD, Luo Y, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK.
    Anticancer Res; 2008 Apr; 28(5A):2625-35. PubMed ID: 19035287
    [Abstract] [Full Text] [Related]

  • 3. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q, Ji M, Zhou J, Jin J, Xue N, Chen J, Xu B, Chen X.
    Biochem Pharmacol; 2016 May 01; 107():29-40. PubMed ID: 26920250
    [Abstract] [Full Text] [Related]

  • 4. Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways.
    Liu X, Han EK, Anderson M, Shi Y, Semizarov D, Wang G, McGonigal T, Roberts L, Lasko L, Palma J, Zhu GD, Penning T, Rosenberg S, Giranda VL, Luo Y, Leverson J, Johnson EF, Shoemaker AR.
    Mol Cancer Res; 2009 Oct 01; 7(10):1686-92. PubMed ID: 19825992
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic effect of TMZ-POH on human nasopharyngeal carcinoma depends on reactive oxygen species accumulation.
    Xie L, Song X, Guo W, Wang X, Wei L, Li Y, Lv L, Wang W, Chen TC, Song X.
    Oncotarget; 2016 Jan 12; 7(2):1651-62. PubMed ID: 26625208
    [Abstract] [Full Text] [Related]

  • 6. Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
    Gupta SK, Mladek AC, Carlson BL, Boakye-Agyeman F, Bakken KK, Kizilbash SH, Schroeder MA, Reid J, Sarkaria JN.
    Clin Cancer Res; 2014 Jul 15; 20(14):3730-41. PubMed ID: 24838527
    [Abstract] [Full Text] [Related]

  • 7. PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
    Luo Q, Li Y, Deng J, Zhang Z.
    Chem Biol Interact; 2015 Jan 25; 226():12-22. PubMed ID: 25499136
    [Abstract] [Full Text] [Related]

  • 8. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
    Dai C, Zhang B, Liu X, Guo K, Ma S, Cai F, Yang Y, Yao Y, Feng M, Bao X, Deng K, Jiao Y, Wei Z, Junji W, Xing B, Lian W, Wang R.
    Int J Cancer; 2013 Oct 15; 133(8):1982-93. PubMed ID: 23564480
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.
    Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y.
    Mol Cancer Res; 2008 Oct 15; 6(10):1621-9. PubMed ID: 18922977
    [Abstract] [Full Text] [Related]

  • 10. ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells.
    Balvers RK, Lamfers ML, Kloezeman JJ, Kleijn A, Berghauser Pont LM, Dirven CM, Leenstra S.
    J Transl Med; 2015 Feb 26; 13():74. PubMed ID: 25886061
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
    Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P, Graziani G.
    BMC Cancer; 2014 Mar 05; 14():151. PubMed ID: 24593254
    [Abstract] [Full Text] [Related]

  • 12. JA, a new type of polyunsaturated fatty acid isolated from Juglans mandshurica Maxim, limits the survival and induces apoptosis of heptocarcinoma cells.
    Gao XL, Lin H, Zhao W, Hou YQ, Bao YL, Song ZB, Sun LG, Tian SY, Liu B, Li YX.
    Apoptosis; 2016 Mar 05; 21(3):340-50. PubMed ID: 26621097
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
    Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G.
    Curr Cancer Drug Targets; 2010 Jun 05; 10(4):368-83. PubMed ID: 20464779
    [Abstract] [Full Text] [Related]

  • 14. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
    Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL.
    Mol Cancer Ther; 2009 Aug 05; 8(8):2232-42. PubMed ID: 19671751
    [Abstract] [Full Text] [Related]

  • 15. Effect of temozolomide on cell viability in gonadotroph adenoma cell lines.
    Ma S, Liu X, Yao Y, Cai F, Dai C, Bao X, Feng M, Wei J, Zhang B, Li G, Ma W, Wang R.
    Oncol Rep; 2011 Sep 05; 26(3):543-50. PubMed ID: 21617871
    [Abstract] [Full Text] [Related]

  • 16. PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
    Engert F, Schneider C, Weiβ LM, Probst M, Fulda S.
    Mol Cancer Ther; 2015 Dec 05; 14(12):2818-30. PubMed ID: 26438158
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
    Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G.
    Mol Pharmacol; 2003 Jan 05; 63(1):192-202. PubMed ID: 12488552
    [Abstract] [Full Text] [Related]

  • 18. PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
    Huang SH, Xiong M, Chen XP, Xiao ZY, Zhao YF, Huang ZY.
    Oncol Rep; 2008 Sep 05; 20(3):567-72. PubMed ID: 18695907
    [Abstract] [Full Text] [Related]

  • 19. 5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
    Hu XY, Liang JY, Guo XJ, Liu L, Guo YB.
    Clin Exp Pharmacol Physiol; 2015 Feb 05; 42(2):146-53. PubMed ID: 25363523
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
    Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z, Hai C.
    Carcinogenesis; 2013 Jun 05; 34(6):1323-30. PubMed ID: 23404993
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.